Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Investing.com - Raymond James has reiterated its Strong Buy rating on Encompass Health Corp (NYSE:EHC) with a price target of $130.00 following the company’s third-quarter 2025 results. The stock currently trades at $114.07, with InvestingPro data showing 9 analysts have revised their earnings upwards for the upcoming period.
The healthcare provider reported adjusted EBITDA of $300 million for the quarter, slightly above the Street consensus of $296 million and in line with Raymond James’ estimate of $299 million.
After accounting for $3 million in out-of-period DPP and $4.3 million in one-time expenses, Encompass Health’s core EBITDA reached $301.4 million, representing approximately a $5 million beat versus consensus expectations.
Management has raised its guidance by $10 million at the midpoint, which suggests fourth-quarter EBITDA of $313 million, aligning with pre-report market expectations.
Raymond James maintains its $130 price target on Encompass Health, representing a multiple of 10.8 times the company’s estimated 2027 EBITDA.
In other recent news, Encompass Health Corp reported its third-quarter 2025 earnings, revealing a slight beat on earnings per share (EPS) forecasts but a flat revenue performance. The company posted an EPS of $1.23, surpassing the forecasted $1.20 by 2.5%. Revenue met expectations, standing at 1.48 billion USD. These results highlight the company’s ability to slightly exceed analyst expectations on earnings, even as revenue remained steady. The earnings announcement is part of the company’s ongoing financial disclosures. This development comes amid various market reactions and assessments by financial analysts. Investors and analysts continue to monitor Encompass Health’s financial performance closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.